Literature DB >> 21802897

Prevalence of secondary lymphedema in patients with head and neck cancer.

Jie Deng1, Sheila H Ridner, Mary S Dietrich, Nancy Wells, Kenneth A Wallston, Robert J Sinard, Anthony J Cmelak, Barbara A Murphy.   

Abstract

CONTEXT: Because surgery, radiation, and/or chemotherapy disrupt lymphatic structures, damage soft tissue leading to scar tissue formation and fibrosis, and further affect lymphatic function, patients with head and neck cancer may be at high risk for developing secondary lymphedema. Yet, no published data are available regarding the prevalence of secondary lymphedema after head and neck cancer treatment.
OBJECTIVES: The aim of this study was to examine prevalence of secondary lymphedema in patients with head and neck cancer.
METHODS: The study included 81 patients with head and neck cancer who were three months or more post-treatment. External lymphedema was staged using Foldi's lymphedema scale. Internal lymphedema was identified through a flexible fiber-optic endoscopic or mirror examination. Patterson's scale was used to grade degrees of internal lymphedema.
RESULTS: Of the 81 patients, 75.3% (61 of 81) had some form of late-effect lymphedema. Of those, 9.8% (6 of 61) only had external, 39.4% (24 of 61) only had internal, and 50.8% (31 of 61) had both types.
CONCLUSION: Lymphedema is a common late effect in patients with head and neck cancer, and it develops in multiple external and internal anatomical locations. During physical examination and endoscopic procedures, clinicians should assess patients with head and neck cancer for late-effect lymphedema. Referral for treatment should be considered when lymphedema is noted. Research is needed to examine risk factors of lymphedema in patients with head and neck cancer and its effects on patients' symptoms, function, and quality of life.
Copyright © 2012 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21802897     DOI: 10.1016/j.jpainsymman.2011.03.019

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  37 in total

1.  Differences of symptoms in head and neck cancer patients with and without lymphedema.

Authors:  Jie Deng; Barbara A Murphy; Mary S Dietrich; Robert J Sinard; Kyle Mannion; Sheila H Ridner
Journal:  Support Care Cancer       Date:  2015-08-29       Impact factor: 3.603

2.  Evaluation of CT Changes in the Head and Neck After Cancer Treatment: Development of a Measurement Tool.

Authors:  Joseph M Aulino; Elizabeth M Wulff-Burchfield; Mary S Dietrich; Sheila H Ridner; Kenneth J Niermann; Jie Deng; Bethany A Rhoten; Jennifer K Doersam; Lee Ann Jarrett; Kyle Mannion; Barbara A Murphy
Journal:  Lymphat Res Biol       Date:  2018-02       Impact factor: 2.589

Review 3.  Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols.

Authors:  Judith A E M Zecha; Judith E Raber-Durlacher; Raj G Nair; Joel B Epstein; Sharon Elad; Michael R Hamblin; Andrei Barasch; Cesar A Migliorati; Dan M J Milstein; Marie-Thérèse Genot; Liset Lansaat; Ron van der Brink; Josep Arnabat-Dominguez; Lisette van der Molen; Irene Jacobi; Judi van Diessen; Jan de Lange; Ludi E Smeele; Mark M Schubert; René-Jean Bensadoun
Journal:  Support Care Cancer       Date:  2016-03-17       Impact factor: 3.603

4.  Body image and depressive symptoms in patients with head and neck cancer: an important relationship.

Authors:  Bethany A Rhoten; Jie Deng; Mary S Dietrich; Barbara Murphy; Sheila H Ridner
Journal:  Support Care Cancer       Date:  2014-06-14       Impact factor: 3.603

5.  Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.

Authors:  Jessica L Geiger; Julie E Bauman; Michael K Gibson; William E Gooding; Prakash Varadarajan; Athanasios Kotsakis; Daniel Martin; Jorge Silvio Gutkind; Matthew L Hedberg; Jennifer R Grandis; Athanassios Argiris
Journal:  Head Neck       Date:  2016-05-27       Impact factor: 3.147

6.  A Prospective Study of the Lymphedema and Fibrosis Continuum in Patients with Head and Neck Cancer.

Authors:  Sheila H Ridner; Mary S Dietrich; Kenneth Niermann; Anthony Cmelak; Kyle Mannion; Barbara Murphy
Journal:  Lymphat Res Biol       Date:  2016-06-15       Impact factor: 2.589

7.  Lymphedema outcomes in patients with head and neck cancer.

Authors:  Brad G Smith; Katherine A Hutcheson; Leila G Little; Roman J Skoracki; David I Rosenthal; Stephen Y Lai; Jan S Lewin
Journal:  Otolaryngol Head Neck Surg       Date:  2014-11-11       Impact factor: 3.497

Review 8.  [Surgical therapy of secondary elephantoid lymphedema of the eyelids].

Authors:  A Sandner; A Lindner
Journal:  HNO       Date:  2015-01       Impact factor: 1.284

9.  A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.

Authors:  Julie E Bauman; Hugo Arias-Pulido; Sang-Joon Lee; M Houman Fekrazad; Hiroyuki Ozawa; Elana Fertig; Jason Howard; Justin Bishop; Hao Wang; Garth T Olson; Michael J Spafford; Dennie V Jones; Christine H Chung
Journal:  Oral Oncol       Date:  2013-02-04       Impact factor: 5.337

10.  A multimodal physical therapy approach to the management of a patient with temporomandibular dysfunction and head and neck lymphedema: a case report.

Authors:  Patricia Crane; Lauren Feinberg; John Morris
Journal:  J Man Manip Ther       Date:  2015-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.